A study in The Journal of Molecular Diagnostics found that liquid biopsy tests can detect lung cancer recurrence months before imaging, using ctDNA analysis to monitor relapse risk in early-stage NSCLC patients.
RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.
The tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
A pooled analysis of more than 1,100 patients across four cohort studies supports the clinical utility of the Nodify CDT test in identifying high-risk lung nodules.
Read More
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Read More
Researchers at Mass General Brigham have developed a blood test that predicts tarlatamab response in small cell lung cancer, showing 85% sensitivity and 100% specificity.
Read More
A study of 431 patients demonstrates the test can detect cancer recurrence months ahead of standard imaging.
Read More
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
Read More
University of Texas at Dallas researchers combine electrochemical biosensors with AI to identify volatile organic compounds linked to thoracic cancers.
Read More
The permit enables the company to offer its PROphetNSCLC test to physicians and patients across New York State, completing nationwide availability.
Read More
A new blood-based test that combines four protein markers with artificial intelligence has demonstrated potential for early lung cancer detection in a multicenter retrospective study.
Read More
On World Lung Day, Reveal Dx board member Mat Brevard discusses why current diagnostic tools fall short—and how new approaches could improve accuracy and outcomes.Â
Read More
The 2,400-patient study evaluates the Percepta Nasal Swab test’s ability to guide management decisions for patients with lung nodules.
Read More
Haystack Oncology and Rutgers Cancer Institute collaborate on phase II trial examining minimal residual disease testing in stage II/III NSCLC patients.
Read More
Study of 177 patients with limited-stage small cell lung cancer demonstrates ctDNA’s potential to personalize consolidation immunotherapy decisions.
Read More
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read More
A case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.
Read More
New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.
Read More